These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 32447743

  • 1. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, Damian D, Dangond F, Cook S.
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [Abstract] [Full Text] [Related]

  • 2. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
    Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
    Leist T, Cook S, Comi G, Montalban X, Giovannoni G, Nolting A, Damian D, Syed S, Galazka A.
    Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971
    [Abstract] [Full Text] [Related]

  • 5. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
    Vukusic S, Coyle PK, Jurgensen S, Truffinet P, Benamor M, Afsar S, Purvis A, Poole EM, Chambers C.
    Mult Scler; 2020 Jun; 26(7):829-836. PubMed ID: 30968734
    [Abstract] [Full Text] [Related]

  • 6. Pregnancy and fetal outcomes following paternal exposure to glatiramer acetate.
    Kaplan S, Dragut CF, Ghimpeteanu A.
    Curr Med Res Opin; 2024 May; 40(5):821-825. PubMed ID: 38577712
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
    Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen JA, Kappos L, Collins W.
    Neurology; 2014 Feb 25; 82(8):674-80. PubMed ID: 24463630
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany.
    Platzbecker K, Wentzell N, Kollhorst B, Haug U.
    Mult Scler Relat Disord; 2022 Nov 25; 67():104184. PubMed ID: 36174258
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P.
    Mult Scler; 2018 Oct 25; 24(12):1594-1604. PubMed ID: 28870107
    [Abstract] [Full Text] [Related]

  • 15. Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
    Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson LA, Leist TP.
    Neurodegener Dis Manag; 2022 Feb 01; 12(1):1-7. PubMed ID: 35019731
    [Abstract] [Full Text] [Related]

  • 16. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F.
    Mult Scler Relat Disord; 2019 Apr 01; 29():168-174. PubMed ID: 30885375
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports.
    Petri M, Landy H, Clowse MEB, Gemzoe K, Khamashta M, Kurtinecz M, Levy RA, Liu A, Marino R, Meizlik P, Pimenta JM, Sumner K, Tilson H, Connolly MB, Wurst K, Harris J, Quasny H, Juliao P, Roth DA.
    Ann Rheum Dis; 2023 Feb 01; 82(2):217-225. PubMed ID: 36198440
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.